库欣病市场在研究期间（2020-2034年）因认知度提高和诊断技术改进，预计将在七大主要市场中实现显著增长-动脉网

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements

CISION 等信源发布 2025-05-16 05:31



可切换为仅中文







The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market..

库欣病的治疗管道中有一些处于中期和后期开发阶段的药物，预计将在不久的将来获得批准。新兴的治疗领域为库欣病的治疗提供了多种替代疗法，包括雷拉科尔兰、氯福曲宾、阿图美兰等。这些疗法的预期上市将进一步对库欣病市场产生积极影响。

LAS VEGAS

拉斯维加斯

，

May 15, 2025

2025年5月15日

/PRNewswire/ -- DelveInsight's

/PRNewswire/ -- DelveInsight的

Cushing's Disease Market Insights

库欣病市场洞察

report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [

报告包括对当前治疗实践、库欣病新兴药物、各疗法的市场份额以及2020年至2034年当前和预测的市场规模的全面理解，分为7个主要市场[

the United States

美国

, the EU4 (

，欧盟4（

Germany

德国

，

France

法国

，

Italy

意大利

, and

，以及

Spain

西班牙

) and the

）和

United Kingdom

英国

, and Japan].

，以及日本]。

Key Takeaways from the Cushing's Disease Market Report

库欣病市场报告的关键要点

According to DelveInsight's analysis, the market size for Cushing's disease was found to be

根据DelveInsight的分析，库欣病的市场容量被发现是

USD 1 billion

10亿美元

in the 7MM in 2024.

在 2024 年的七大市场（7MM）中。

In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by

2024年，在所有库欣病的当前疗法中，收入最高的是

Mifepristone (KORLYM and generics)

米非司酮（KORLYM及仿制药）

in the US.

在美国。

Based on DelveInsight's assessment in 2024, the 7MM had approximately

基于DelveInsight在2024年的评估，7MM大约有

37K

diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034).

诊断为库欣病的流行病例。由于在预测期内（2025-2034年）诊断能力的提高和对这种疾病的认识增强，这些病例预计将会增加。

Leading Cushing's disease companies developing emerging therapies, such as

领先的库欣病公司正在开发新兴疗法，例如

Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics,

科皮克特制药、麻雀制药、克里内特制药、H. Lundbeck、斯特罗制药，

and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years.

和其他公司正在开发新型的库欣病药物，这些药物可能在未来几年内进入库欣病市场。

The promising Cushing's disease therapies in the pipeline include

有希望的库欣病疗法在研发管线中包括

DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat,

DUPIXENT（度普利尤单抗）、Linerixibat（GSK2330672）、NEMLUVIO/MITCHGA（奈莫利珠单抗）、Volixibat，

and others.

和其他人。

在

March 2025

2025年3月

, Corcept Therapeutics

，Corcept Therapeutics公司

announced that the FDA had assigned a PDUFA target action date of

宣布FDA已指定PDUFA目标行动日期为

December 30, 2025

2025年12月30日

, for relacorilant to treat patients with endogenous hypercortisolism.

，用于治疗内源性高皮质醇症患者。

在

February 2025

2025年2月

, Crinetics Pharmaceuticals

，克里内蒂克斯制药公司

mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026.

提到该公司预计将在2025年底或2026年初开始库欣病Atumelnant（CRN04894）的Ib/IIa期试验的患者招募。

在

October 2024

2024年10月

, Sparrow Pharmaceuticals

，麻雀制药公司

announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome.

宣布氯氟曲班（clofutriben）已获得美国FDA授予的孤儿药资格（ODD），用于治疗内源性库欣综合征。

Discover which therapies are expected to grab the major Cushing's disease market share @

发现哪些疗法有望占据主要的库欣病市场份额 @

Cushing's Disease Market Report

库欣病市场报告

Cushing's Disease Overview

库欣病概述

Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas.

库欣病是一种罕见但严重的内分泌疾病，由垂体肿瘤引发过量皮质醇分泌所致。其症状包括体重增加、疲劳、情绪障碍、高血压和葡萄糖耐受不良等。库欣综合征占高皮质醇症病例的80%-85%，其中75%-80%与分泌ACTH的垂体腺瘤相关。

Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies..

未经治疗，5年生存率仅为约50%，凸显了对有效疗法的迫切需求。

Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years.

诊断库欣病尤其困难，因为它很罕见，与其他疾病有相似症状，并且表现形式多样。只有40%-60%的患者在标准磁共振成像（MRI）上能检测到肿瘤，而且诊断平均延迟7年。

Cushing's Disease Epidemiology Segmentation

库欣病流行病学细分

The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

库欣病的流行病学部分提供了对历史和当前库欣病患者群体的洞察，并预测了七大主要市场（7MM）的趋势。通过探讨多项研究和关键意见领袖的观点，它有助于识别当前和预测的患者趋势的原因。

The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

库欣病市场报告提供了2020-2034年研究期间在七大市场（7MM）中的流行病学分析，分为以下部分：

Total Prevalent Cases of Cushing's Disease

库欣病的总流行病例数

Total Diagnosed Prevalent Cases of Cushing's Disease

库欣病总诊断患病数

Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease

库欣病性别特异性确诊病例的患病率

Age-Specific Diagnosed Prevalent Cases of Cushing's Disease

库欣病的年龄特异性诊断患病数

Cushing's Disease Treatment Market

库欣病治疗市场

The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels.

库欣病的主要治疗方法通常是经蝶手术切除垂体肿瘤，这通常可以导致病情缓解。然而，部分患者可能会出现复发。当手术不成功或不可行时，会使用药物治疗来控制皮质醇水平。

Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is

多种药物可用于管理库欣病，尤其是在手术无效或不可行的情况下。其中一种药物是

KORLYM

科瑞姆

, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by

，由Corcept Therapeutics开发，用于治疗库欣综合征中同时患有2型糖尿病或葡萄糖不耐受的高血糖患者。2024年，一款仿制药由

Teva Pharmaceuticals

梯瓦制药

entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include S

进入市场，增加了竞争，Corcept公司自己也推出了仿制药版本。其他获批的选择包括S

IGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV.

IGNIFOR 和 SIGNIFOR LAR，ISTURISA，以及 RECORLEV。

In addition, off-label drugs like

此外，超说明书用药如

ketoconazole, metyrapone, cabergoline, mitotane, and etomidate

酮康唑、美替拉酮、卡麦角林、米托坦和依托咪酯

are also used in the U.S., with some marketed in

在美国也被使用，其中一些已上市

Europe

欧洲

by HRA Pharma.

由HRA制药公司生产。

SIGNIFOR (pasireotide)

SIGNIFOR（帕西瑞肽）

, developed by

，由开发

Recordati

记录在案

, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and

，是2012年FDA首个特别批准用于库欣病的药物，同时也获得了欧盟的批准。Recordati还销售SIGNIFOR LAR，这是一种长效注射版本，已获得FDA批准，并且

Japan's

日本的

PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route.

2018年获得PMDA批准。该配方每四周通过肌肉注射给药一次，与SIGNIFOR具有相同的机制，但提供了不同的给药途径。

Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is

Recordati在这一治疗领域被公认为是领先者。该公司另一个关键产品是

ISTURISA (osilodrostat)

ISTURISA（奥西洛司他）

, the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900)..

，这是第一个获FDA批准的口服药物，通过靶向参与皮质醇合成最后一步的酶11β-羟化酶（CYP11B1）来抑制皮质醇的产生。相比注射疗法，其口服给药方式对患者来说更加方便。ISTURISA目前也在一项正在进行的II期试验（NCT03708900）中被研究用于儿科治疗。

RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action..

RECORLEV最初由Strongbridge生物制药公司开发，后被Xeris制药公司收购，于2021年获得FDA批准。它适用于内源性库欣综合症成人患者，这些患者不适合手术或通过手术未能治愈。与ISTURISA不同，RECORLEV通过在类固醇生成途径的多个点抑制皮质醇的产生，提供了独特的作用机制。

To know more about Cushing's disease treatment guidelines, visit @

要了解更多关于库欣病治疗指南的信息，请访问 @

Cushing's Disease Management

库欣病管理

Cushing's Disease Pipeline Therapies and Key Companies

库欣病的在研疗法和关键公司

Relacorilant (CORT125134): Corcept Therapeutics

Clofutriben (SPI-62): Sparrow Pharmaceuticals

氯福曲本（SPI-62）：麻雀制药公司

Atumelnant (CRN04894): Crinetics Pharmaceuticals

阿图美兰特（CRN04894）：克里内蒂克斯制药公司

Lu AG13909: H. Lundbeck

Lu AG13909：H. Lundbeck

ST-002: Stero Therapeutics

ST-002：Stero Therapeutics

Discover more about Cushing's disease drugs in development @

了解更多关于库欣病在研药物的信息 @

Cushing's Disease Clinical Trials

库欣病临床试验

Cushing's Disease Market Dynamics

库欣病市场动态

The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition,

库欣病市场动态预计将在未来几年发生变化。尽管库欣病通常被认为是一种罕见病，

growing awareness and recent advances in research

日益增长的认识和研究的最新进展

suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments

暗示未来诊断可能会增加；尽管市场看似拥挤，但许多当前的高皮质醇症治疗方案

fail to normalize cortisol levels

未能使皮质醇水平恢复正常

effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the

有效且显著的副作用凸显了创新的巨大机会，特别是考虑到这一点时，

limited therapies specifically targeting Cushing's disease

针对库欣病的治疗方法有限

and the potential of newer oral alternatives like

以及像新型口服替代品这样的潜力，

ISTURISA and RECORLEV

ISTURISA 和 RECORLEV

to offer greater flexibility compared to SC and intramuscular options such as

与皮下注射和肌肉注射等选项相比，提供了更大的灵活性

SIGNIFOR and SIGNIFOR LAR

SIGNIFOR和SIGNIFOR LAR

。

Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the

此外，正在研究治疗库欣病的潜在疗法，可以肯定地预测，在预测期内，治疗领域将对库欣病市场产生重大影响。而且，

anticipated introduction of emerging therapies

预计新兴疗法的引入

with improved efficacy and a further

随着疗效的提高和进一步的

improvement in the diagnosis rate

诊断率的提高

are expected to drive the growth of the Cushing's disease market in the 7MM.

预计将在7MM中推动库欣病市场的发展。

However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often

然而，有几个因素可能会阻碍库欣病市场的发展。由于指南和建议的非特异性，库欣病患者常常...

face suboptimal care, delayed diagnosis, and inconsistent treatment approaches

面临次优的护理、诊断延误和治疗方案不一致的问题

, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many

，再加上诊断的复杂性、频繁的误诊以及与更常见病症的症状重叠，使得许多

undiagnosed or untreated

未确诊或未经治疗的

; while existing therapies such as

；而现有的治疗方法，如

ketoconazole and metyrapone

酮康唑和美替拉酮

approved in

批准于

Europe

欧洲

based on limited retrospective data and

基于有限的回顾性数据和

used off-label

超说明书使用

in the US despite

在美国，尽管

high costs

高成本

are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies.

在临床实践中被广泛信任和根深蒂固，对新兴疗法的采用构成了重大障碍。

Moreover, Cushing's disease treatment poses a

此外，库欣病的治疗面临一个难题。

significant economic burden

显著的经济负担

and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by

并且会破坏患者的整体健康和生活质量。此外，库欣病市场增长可能会被

failures and discontinuation of emerging therapies

新兴疗法的失败与中断

，

unaffordable pricing

无法承受的定价

，

market access and reimbursement issues

市场准入和报销问题

, and a

，以及一个

shortage of healthcare specialists

医疗保健专家短缺

. In addition, the

此外，

undiagnosed, unreported cases and the unawareness

未确诊、未报告的病例以及缺乏认识

about the disease may also impact the Cushing's disease market growth.

关于该疾病的信息也可能影响库欣病市场增长。

Cushing's Disease Market Report Metrics

库欣病市场报告指标

Details

详情

Study Period

学习期

2020–2034

Coverage

覆盖范围

7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].

7国集团 [美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本]。

Cushing's Disease Market Size in 2024

2024年库欣病市场规模

USD 1 Billion

10亿美元

Key Cushing's Disease Companies

库欣病关键公司

Xeris Pharmaceuticals, Recordati, Corcept Therapeutics, Sparrow Pharmaceuticals, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others

谢里斯制药、Recordati、Corcept治疗、Sparrow制药、H. Lundbeck、Stero治疗、Crinetics制药等

Key Cushing's Disease Therapies

库欣病的关键疗法

RECORLEV, ISTURISA, SIGNIFOR, SIGNIFOR LAR, KORLYM, Relacorilant, Clofutriben, Lu AG13909, ST-002, Atumelnant, and others

RECORLEV、ISTURISA、SIGNIFOR、SIGNIFOR LAR、KORLYM、Relacorilant、Clofutriben、Lu AG13909、ST-002、Atumelnant，以及其他药物

Scope of the

范围

Cushing's Disease

库欣病

Market Report

市场报告

Therapeutic Assessment:

治疗评估：

Cushing's Disease current marketed and emerging therapies

库欣病当前市场上的和新兴的疗法

Cushing's Disease

库欣病

Market Dynamics:

市场动态：

Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook

新兴库欣病药物的关键市场预测假设和市场展望

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement

未满足的需求、关键意见领袖的观点、分析师的观点、库欣病市场准入和报销

Download the report to understand which factors are driving Cushing's disease market trends @

下载报告以了解哪些因素正在推动库欣病市场趋势 @

Cushing's Disease Market Trends

库欣病市场趋势

Table of Contents

Key Insights

关键见解

Report Introduction

报告介绍

Executive Summary

执行摘要

Key Events

关键事件

Epidemiology and Market Forecast Methodology

流行病学与市场预测方法论

Cushing's Disease Market Overview at a Glance

库欣病市场概况一览

6.1

Market Share (%) Distribution by Therapies of Cushing's Disease in 2024

2024年库欣病治疗市场占有率（%）分布

6.2

Market Share (%) Distribution by Therapies of Cushing's Disease in 2034

2034年库欣病治疗市场占有率（%）分布

Disease Background and Overview

疾病背景与概述

7.1

Introduction

简介

7.2

Clinical and Biological Characteristics

临床和生物学特性

7.3

Genetics of Cushing's Disease

库欣病的遗传学

7.4

Pathogenesis and Pathophysiology

发病机制与病理生理学

7.5

Complications of Cushing's Disease

库欣病的并发症

7.6

Diagnosis of Cushing's Disease

库欣病的诊断

7.6.1

Diagnostic Algorithm

诊断算法

7.7

Treatment and Management of Cushing's Disease

库欣病的治疗与管理

7.7.1

Treatment Algorithm of Cushing's Disease

库欣病的治疗算法

Guidelines, Recommendations, and Management for Cushing's Disease

库欣病的指南、建议和管理

8.1

Consensus on Diagnosis and Management of Cushing's Disease: A Guideline Update (2020) (The United States)

库欣病诊断与管理共识：2020年指南更新（美国）

8.2

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline (2015) (Europe)

库欣综合征的治疗：内分泌学会临床实践指南（2015）（欧洲）

8.3

Clinical Significance of Screening for Subclinical Cushing's Disease in Patients With Pituitary Tumors (2010) (Japan)

垂体肿瘤患者亚临床库欣病筛查的临床意义（2010）（日本）

九

Epidemiology and Patient Population

流行病学与患者群体

9.1

Key Findings

关键发现

9.2

Assumptions and Rationales

假设与理由

9.3

Total Diagnosed Prevalent Cases of Cushing's Disease in the 7MM

7MM中库欣病的总诊断患病数

9.4

The United States

美国

9.4.1

Total Diagnosed Prevalent Cases of Cushing's Disease in the US

美国库欣病的总诊断患病数

9.4.2

Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in the US

美国库欣病按性别诊断的患病病例数

9.4.3

Age-specific Diagnosed Prevalent Cases of Cushing's Disease in the US

美国库欣病的年龄特异性诊断患病人数

9.5

EU4 and the UK

EU4 与英国

9.5.1

Total Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK

欧盟四大国家和英国库欣病的总诊断患病人数

9.5.2

Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK

欧盟四大国及英国库欣病性别特异性确诊病例数

9.5.3

Age-specific Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK

欧盟四国和英国库欣病的年龄别诊断患病数

9.6

Japan

日本

9.6.1

Total Diagnosed Prevalent Cases of Cushing's Disease in Japan

日本库欣病总诊断患病数

9.6.2

Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in Japan

日本库欣病按性别诊断的患病病例

9.6.3

Age-specific Diagnosed Prevalent Cases of Cushing's Disease in Japan

日本库欣病的年龄特异性诊断患病病例

Patient Journey

患者旅程

Marketed Drug

上市药品

11.1

Marketed Drug Details

上市药品详情

11.2

ISTURISA (osilodrostat): Recordati

ISTURISA（osilodrostat）：Recordati

11.2.1

Product Description

产品描述

11.2.2

Regulatory Milestones

监管里程碑

11.2.3

Other Developmental Activities

其他开发活动

11.2.4

Clinical Development Activities

临床开发活动

11.2.4.1

Clinical Trials Information

临床试验信息

11.2.5

Safety and Efficacy

安全性与有效性

11.3

RECORLEV (levoketoconazole): Xeris Pharmaceuticals

RECORLEV（左酮康唑）：Xeris Pharmaceuticals

11.3.1

Product Description

产品描述

11.3.2

Regulatory Milestones

监管里程碑

11.3.3

Other Developmental Activities

其他开发活动

11.3.4

Safety and Efficacy

安全性与有效性

11.4

SIGNIFOR (pasireotide): Recordati

SIGNIFOR（帕西瑞肽）：Recordati

11.4.1

Product Description

产品描述

11.4.2

Regulatory Milestones

监管里程碑

11.4.3

Other Developmental Activities

其他开发活动

11.4.4

Safety and Efficacy

安全性与有效性

11.5

SIGNIFOR LAR (pasireotide pamoate): Recordati

SIGNIFOR LAR（帕西瑞肽帕莫酸盐）：Recordati

11.5.1

Product Description

产品描述

11.5.2

Regulatory Milestones

监管里程碑

11.5.3

Other Developmental Activities

其他开发活动

11.5.4

Safety and Efficacy

安全性与有效性

十二

Emerging Drugs

新兴药物

12.1

Key Cross Competition

关键交叉竞争

12.2

Relacorilant (CORT125134): Corcept Therapeutics

12.2.1

Product Description

产品描述

12.2.2

Other Development Activity

其他开发活动

12.2.3

Clinical Development

临床开发

12.2.3.1

Clinical Trial Information

临床试验信息

12.2.4

Safety and Efficacy

安全性与有效性

12.3

Clofutriben (SPI-62): Sparrow Pharmaceuticals

氯福曲本 (SPI-62): 麻雀制药

12.3.1

Product Description

产品描述

12.3.2

Other Development Activity

其他开发活动

12.3.3

Clinical Development

临床开发

12.3.3.1

Clinical Trial Information

临床试验信息

12.3.4

Safety and Efficacy

安全性与有效性

12.4

Atumelnant (CRN04894): Crinetics Pharmaceuticals

阿图美南特（CRN04894）：Crinetics Pharmaceuticals

12.4.1

Product Description

产品描述

12.4.2

Other Development Activity

其他开发活动

12.4.3

Clinical Development

临床开发

12.4.3.1

Clinical Trial Information

临床试验信息

12.4.4

Safety and Efficacy

安全性与有效性

Cushing's Disease: Seven Major Market Analysis

库欣病：七大市场分析

13.1

Key Findings

主要发现

13.2

Market Outlook

市场展望

13.3

Key Market Forecast Assumptions

关键市场预测假设

13.3.1

Cost Assumptions and Rebates

成本假设与回扣

13.3.2

Pricing Trends

价格趋势

13.3.3

Analogue Assessment

模拟评估

13.3.4

Launch Year and Therapy Uptakes

上市年份与治疗吸收情况

13.4

Conjoint Analysis

联合分析

13.5

Total Market Size of Cushing's Disease in the 7MM

七大市场库欣病的总市场规模

13.6

Market Size of Cushing's Disease by Therapies in 7MM

七大市场中库欣病的疗法市场规模

13.7

The United States

美国

13.7.1

Total Market Size of Cushing's Disease in the US

美国库欣病的总市场规模

13.7.2

Market Size of Cushing's Disease by Therapies in the US

美国库欣病治疗药物的市场规模

13.8

EU4 and the UK

EU4 和英国

13.8.1

Total Market Size of Cushing's Disease in the EU4 and the UK

欧盟四国和英国库欣病的总市场规模

13.8.2

Market Size of Cushing's Disease by Therapies in EU4 and the UK

欧盟四个国家和英国库欣病治疗市场规模

13.9

Japan

日本

13.9.1

Total Market Size of Cushing's Disease in Japan

日本库欣病的总市场规模

13.9.2

The Market Size of Cushing's Disease by Therapies in Japan

日本库欣病治疗市场的规模

Unmet Needs

未满足的需求

SWOT Analysis

SWOT分析

KOL Views

KOL观点

Market Access and Reimbursement

市场准入与报销

17.1

The United States

美国

17.1.1

Centre for Medicare and Medicaid Services (CMS)

医疗保险和医疗补助服务中心 (CMS)

17.2

EU4 and the UK

EU4 和英国

17.2.1

Germany

德国

17.2.2

France

法国

17.2.3

Italy

意大利

17.2.4

Spain

西班牙

17.2.5

United Kingdom

英国

17.3

Japan

日本

17.3.1

MHLW

厚生劳动省

17.4

Market Access and Reimbursement of Cushing's Disease

库欣病的市场准入与报销政策

Appendix

附录

18.1

Bibliography

参考文献

18.2

Report Methodology

报告方法论

DelveInsight Capabilities

德维尔洞察力

Disclaimer

免责声明

About DelveInsight

关于DelveInsight

Related Reports

关联报告

Cushing's Syndrome Market

库欣综合征市场

Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast

库欣综合征市场洞察、流行病学与市场预测

– 2034

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including

报告深入理解了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键的库欣综合症公司，包括

Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics,

科勒普特制药、克里内特克斯制药、赛克拉塞尔制药、斯帕罗制药、斯特罗治疗学、

among others.

其中包括。

Cushing's Syndrome Pipeline

库欣综合征药物研发管线

Cushing's Syndrome Pipeline Insight – 2025

库欣综合征研发管线洞察——2025

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including

报告提供了关于研发管线的全面见解，包括临床和非临床阶段产品的管线药物概况，以及关键的库欣综合症公司，包括

Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics,

科勒普特制药、克里内克斯制药、赛克拉塞尔制药、斯帕罗制药、斯特罗治疗学、

among others.

其中包括。

Endogenous Cushing's Syndrome Market

内源性库欣综合征市场

Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast

内源性库欣综合征市场洞察、流行病学与市场预测

– 2034

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including

报告深入理解了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的内源性库欣综合症公司，包括

Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals,

科勒普特制药、克里内蒂克斯制药、斯派罗制药，

among others.

其中包括。

Endogenous Cushing's Syndrome Pipeline

内源性库欣综合征管线

Endogenous Cushing's Syndrome Pipeline Insight – 2025

内源性库欣综合征研发管线洞察——2025

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including

报告提供了关于研发管线的全面见解，包括临床和非临床阶段产品的管线药物概况，以及关键的内源性库欣综合症公司，包括

Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals,

科瑞普特制药、克里内蒂克斯制药、斯帕罗制药、

among others.

其中包括。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

德尔维洞察（DelveInsight）是一家专注于生命科学领域的领先商业咨询和市场研究公司。它通过提供全面的端到端解决方案来支持制药公司以提升其业绩。通过我们的订阅平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

。

联系我们

Shruti Thakur

舒鲁蒂·塔库尔

info@delveinsight.com

+14699457679

www.delveinsight.com

Logo:

标志：

https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP